Abpro Holdings, Inc.

Abpro Holdings is a biotechnology company developing novel antibody constructs for immuno-oncology and ophthalmology applications. The company operates two core technology platforms: DiversImmune, which generates a collection of proprietary antibodies against validated and novel targets, and MultiMab, an engineering platform that enables the creation of multi-specific antibody constructs by combining antibody building blocks in various configurations. This approach allows the company to design therapeutics with dual targeting capabilities tailored to specific clinical needs.

The company's pipeline centers on TetraBi antibody formats, a proprietary construct type designed to engage multiple targets simultaneously. Lead candidates include ABP-102, targeting HER2 and CD3 for HER2-positive solid tumors such as breast and gastric cancers; ABP-201, targeting VEGF and ANG-2 for ophthalmology indications including diabetic macular edema and wet age-related macular degeneration; ABP-110, targeting GPC3 and CD3 for hepatocellular carcinoma; and ABP-150, targeting claudin 18.2 and CD3 for gastric cancer. The company maintains strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc.

Abpro Holdings operates as a small-scale biotechnology firm with six full-time employees and is headquartered in Woburn, Massachusetts. The company was incorporated in Delaware in 2004 and is listed on Nasdaq.